Latest Breaking News On - European medicines agency summary of product characteristics - Page 1 : comparemela.com

Globally regarded soft-tissue sarcoma therapy has been approved by Medsafe for New Zealand patients YONDELIS(trabectedin) demonstrates 45% reduction in risk of disease progression or death versus dacarbazine[1] SINGAPORE and AUCKLAND, New Zealand, Feb. 17, 2023 /PRNewswire/ Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce that its portfolio therapy to treat rare soft tissue sarcomas has now been approved in New Zealand. Medsafe has approved the use of YONDELIS (trabectedin) "for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen".[2] YONDELIS (trabectedin) is used extensively around the world and has been shown to improve progression free survival[1]. News of the Medsafe registration has been welcomed by oncologists and the New Zealand sarcoma community, who say it means patients whose disease has progressed will have access to a new line of th

United statesNew zealandCarlo montagnerDenise carusoJayesh desaiAustralia therapeutic goods administrationCancer council victoria fact sheetEuropean medicines agency summary of product characteristicsZealand sarcoma associationSpecialised therapeuticsAssociate professor jayesh desaiMedical oncologistDeputy chairNew zealand sarcoma associationExecutive officer dr denise carusoTherapeutic goods administration